Geron’s Insider Moves Signal Strong Pipeline Focus & Strategic Growth Ahead
Geron’s latest insider filings show strategic stock‑option grants and CFO liquidity moves aimed at keeping R&D on track for its telomerase‑inhibitor oncology pipeline, while highlighting potential upside if key development milestones are achieved.
4 minutes to read